In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Neurometrix (NURO), with a price target of $5. The company’s shares closed yesterday at $0.82.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.2% and a 44.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Neurometrix has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
Based on Neurometrix’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $2.8 million. In comparison, last year the company had a net profit of $1.17 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NeuroMetrix, Inc. is a healthcare company, which engages in the research, development, and trade of medical equipment and consumables. It offers an over-the-counter wearable therapeutic device for chronic pain, the Quell Health Cloud, DPNCheck, and pain management devices to treat chronic pain, nerve diseases, and sleep disorder.
